Adamas reports positive PII/III data for ADS-5102
This article was originally published in Scrip
Adamas Pharmaceuticals reported final Phase II/III data that show statistically significant improvements versus placebo in levodopa-induced dyskinesia (LID) for Parkinson's disease patients treated with ADS-5102 (Nurelin), an extended-release version of the generic Parkinson's drug amantadine.
You may also be interested in...
Private Company Edition: VC deals fell short of the record-breaking level seen in 2018 and financings may slow a bit more in 2020. Also, UPMC and Frazier close new VC funds, and Emendo raises $61m for gene-editing platform.
Monia told Scrip at the J.P. Morgan Healthcare Conference that the company will be more selective about partnerships going forward and build commercial capabilities to market Ionis-owned drugs.
Aimovig, Emgality and Ajovy have been on the market for more than a year, but are still far from blockbusters even though millions of patients are eligible for treatment – and at least one new competitor is coming.